Lenalidomide in Chronic Lymphocytic Leukemia (CLL) Patients With Residual Disease

Phase 2 Completed 33 enrolled M.D. Anderson Cancer Center Celgene Corporation · collab

NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to learn if Revlimid (lenalidomide) can help to reduce the level of leukemia in your body. The safety of this drug will also be studied.

Timeline

Start: 2008-02
Primary completion: 2015-10
Completion: 2015-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Lenalidomide	Other / unclassified	10 mg	Oral

Lenalidomide in Chronic Lymphocytic Leukemia (CLL) Patients With Residual Disease

Summary

Timeline

Drugs

Indications